• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫检查点抑制剂引起的免疫相关性肠道假性梗阻：病例报告

Immune-related intestinal pseudo-obstruction caused by immune checkpoint inhibitors: case report.

作者信息

Qian Yimeng, Zhi Zheng, Ai Jing, Kang Lin, Qiu Gang, Huang Xin, Zhao Jing

机构信息

Department of Oncology, Hebei General Hospital, Shijiazhuang, China.

Graduate School, Hebei North University, Zhangjiakou, China.

出版信息

Front Oncol. 2024 Aug 14;14:1415117. doi: 10.3389/fonc.2024.1415117. eCollection 2024.

DOI:10.3389/fonc.2024.1415117
PMID:39206160
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11349563/
Abstract

Intestinal obstruction, a rare manifestation of immunotherapy-related gastrointestinal adverse events, can be severe and even life-threatening with intestinal perforation. We present a 64-year-old man with HCC and currently under the therapy with Pembrolizumab, who was admitted in our hospital with abdominal distension. Radiologic findings were consistent with small bowel ileus. After conservative treatment, the patient underwent colonoscopy where no cause of ileus was discovered. The patient received high-dose prednisone due to the side effects of immune checkpoint inhibitor therapy. This resulted in a gradual improvement of symptoms.

摘要

肠梗阻是免疫治疗相关胃肠道不良事件的一种罕见表现，可能很严重，甚至因肠穿孔而危及生命。我们报告一名64岁的肝癌男性患者，目前正在接受帕博利珠单抗治疗，因腹胀入院。影像学检查结果与小肠肠梗阻相符。保守治疗后，患者接受了结肠镜检查，但未发现肠梗阻的病因。由于免疫检查点抑制剂治疗的副作用，患者接受了大剂量泼尼松治疗。这导致症状逐渐改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f9/11349563/418904e9344e/fonc-14-1415117-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f9/11349563/c5860dd88908/fonc-14-1415117-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f9/11349563/171d5c30ba2a/fonc-14-1415117-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f9/11349563/4f8124da7734/fonc-14-1415117-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f9/11349563/418904e9344e/fonc-14-1415117-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f9/11349563/c5860dd88908/fonc-14-1415117-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f9/11349563/171d5c30ba2a/fonc-14-1415117-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f9/11349563/4f8124da7734/fonc-14-1415117-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9f9/11349563/418904e9344e/fonc-14-1415117-g004.jpg

相似文献

1
Immune-related intestinal pseudo-obstruction caused by immune checkpoint inhibitors: case report.免疫检查点抑制剂引起的免疫相关性肠道假性梗阻：病例报告
Front Oncol. 2024 Aug 14;14:1415117. doi: 10.3389/fonc.2024.1415117. eCollection 2024.
2
Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.一名肺癌患者中与纳武单抗治疗相关的免疫相关性肠道假性梗阻
J Oncol Pharm Pract. 2019 Mar;25(2):487-491. doi: 10.1177/1078155217738325. Epub 2017 Oct 25.
3
Case report: reinitiating pembrolizumab treatment after small bowel perforation.病例报告：小肠穿孔后重新开始使用派姆单抗治疗。
BMC Cancer. 2019 Apr 24;19(1):379. doi: 10.1186/s12885-019-5577-5.
4
Immune checkpoint inhibitor-induced anti-Hu antibody-associated gastrointestinal pseudo-obstruction: a case report and literature review.免疫检查点抑制剂诱导的抗Hu抗体相关胃肠道假性梗阻：一例报告及文献综述。
Front Immunol. 2025 Apr 1;16:1555790. doi: 10.3389/fimmu.2025.1555790. eCollection 2025.
5
Enteric plexus neuropathy associated with PD-L1 blockade in a patient with small-cell lung cancer.与小细胞肺癌患者的 PD-L1 阻断相关的肠神经丛神经病。
Immunotherapy. 2021 Sep;13(13):1085-1092. doi: 10.2217/imt-2020-0350. Epub 2021 Jul 12.
6
Pseudoprogression presenting as intestinal perforation in non-small cell lung cancer treated with anti-PD-1: A case report.抗PD-1治疗的非小细胞肺癌中表现为肠穿孔的假性进展：一例报告
Mol Clin Oncol. 2019 Aug;11(2):132-134. doi: 10.3892/mco.2019.1871. Epub 2019 May 31.
7
Intestinal perforation in recurrent cervical cancer following bevacizumab and pembrolizumab therapy: A case report.贝伐单抗和派姆单抗治疗后复发性宫颈癌并发肠穿孔：一例报告
Medicine (Baltimore). 2025 Apr 11;104(15):e40473. doi: 10.1097/MD.0000000000040473.
8
Chronic intestinal pseudo-obstruction.慢性肠道假性梗阻
Dig Dis. 1995 May-Jun;13(3):163-81. doi: 10.1159/000171499.
9
Faecal retention: a common cause in functional bowel disorders, appendicitis and haemorrhoids--with medical and surgical therapy.粪便潴留：功能性肠病、阑尾炎和痔疮的常见病因——兼论内科及外科治疗
Dan Med J. 2015 Mar;62(3).
10
Acute colonic ileus (pseudo-obstruction) in renal transplant recipients.肾移植受者的急性结肠肠梗阻（假性梗阻）
Surgery. 1988 Oct;104(4):616-23.

引用本文的文献

1
Commentary: Immune-related intestinal pseudo-obstruction caused by immune checkpoint inhibitors: case report.评论：免疫检查点抑制剂引起的免疫相关肠道假性梗阻：病例报告。
Front Oncol. 2025 May 23;15:1543608. doi: 10.3389/fonc.2025.1543608. eCollection 2025.
2
Immune checkpoint inhibitor-induced anti-Hu antibody-associated gastrointestinal pseudo-obstruction: a case report and literature review.免疫检查点抑制剂诱导的抗Hu抗体相关胃肠道假性梗阻：一例报告及文献综述。
Front Immunol. 2025 Apr 1;16:1555790. doi: 10.3389/fimmu.2025.1555790. eCollection 2025.
3
Successful Resection of Small Intestinal Stenosis After Treatment With an Immune Checkpoint Inhibitor for Metastatic Lung Cancer in the Small Intestine: A Case Report.

本文引用的文献

1
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.乐卫玛联合帕博利珠单抗对比乐卫玛联合安慰剂用于治疗晚期肝细胞癌（LEAP-002）：一项随机、双盲、III 期临床试验。
Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2.
2
Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review.癌症患者接受免疫检查点抑制剂治疗后的慢性免疫相关不良事件：系统评价。
J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2022-006500.
3
Treatment of steroid-refractory immune checkpoint inhibitor-induced intestinal pseudo-obstruction with infliximab.
免疫检查点抑制剂治疗小肠转移性肺癌后小肠狭窄的成功切除：一例报告
Cureus. 2024 Dec 17;16(12):e75909. doi: 10.7759/cureus.75909. eCollection 2024 Dec.
4
A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib.一项来自FAERS数据库的真实世界药物安全性监测研究，涉及单独接受帕博利珠单抗以及联合乐伐替尼治疗的肝细胞癌患者。
Sci Rep. 2025 Jan 9;15(1):1425. doi: 10.1038/s41598-025-85831-4.
英夫利昔单抗治疗类固醇难治性免疫检查点抑制剂诱导的肠道假性梗阻
Rev Esp Enferm Dig. 2024 Jul;116(7):383-384. doi: 10.17235/reed.2023.9796/2023.
4
Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities.检查点抑制剂免疫相关不良反应：自身抗体和 B 细胞作为生物标志物的重点综述，进展和未来的可能性。
Front Immunol. 2023 Jan 11;13:991433. doi: 10.3389/fimmu.2022.991433. eCollection 2022.
5
Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events.免疫检查点抑制剂相关不良事件的特征及预测因素分析
Cancer Biol Med. 2021 Jul 14;18(4):1118-33. doi: 10.20892/j.issn.2095-3941.2021.0052.
6
Enteric plexus neuropathy associated with PD-L1 blockade in a patient with small-cell lung cancer.与小细胞肺癌患者的 PD-L1 阻断相关的肠神经丛神经病。
Immunotherapy. 2021 Sep;13(13):1085-1092. doi: 10.2217/imt-2020-0350. Epub 2021 Jul 12.
7
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance.从免疫相关不良事件的真实世界研究中吸取的经验教训：药物警戒的临床视角。
Target Oncol. 2020 Aug;15(4):449-466. doi: 10.1007/s11523-020-00738-6.
8
Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.影响肿瘤应答者的因素和接受免疫检查点抑制剂治疗的癌症患者毒性的预测生物标志物。
Int Immunopharmacol. 2020 Aug;85:106628. doi: 10.1016/j.intimp.2020.106628. Epub 2020 May 28.
9
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.免疫检查点抑制剂免疫相关不良事件的临床特征与治疗
Immune Netw. 2020 Feb 17;20(1):e9. doi: 10.4110/in.2020.20.e9. eCollection 2020 Feb.
10
Chronic intestinal pseudo-obstruction in a patient with metastatic gastro-oesophageal junction cancer receiving treatment with pembrolizumab.一名接受帕博利珠单抗治疗的转移性胃食管交界癌患者出现慢性肠道假性梗阻。
BMJ Case Rep. 2019 Dec 15;12(12):e232388. doi: 10.1136/bcr-2019-232388.